Last reviewed · How we verify
17β-estradiol 10 mcg
17β-estradiol 10 mcg, developed by Mahidol University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position is bolstered by its established presence, though specific revenue figures are not provided. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | 17β-estradiol 10 mcg |
|---|---|
| Also known as | Femiest® |
| Sponsor | Mahidol University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Postpartum Vaginal Estrogen for Breastfeeding Patients (PHASE4)
- Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder (PHASE4)
- REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy (PHASE2)
- Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections (PHASE4)
- A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants (PHASE1)
- Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
- Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT) (NA)
- LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 17β-estradiol 10 mcg CI brief — competitive landscape report
- 17β-estradiol 10 mcg updates RSS · CI watch RSS
- Mahidol University portfolio CI